Aoi Matsuda, Ryuichi Masuzawa, Kazuya Takahashi, Kazunori Takano, Takeshi Endo. MEK inhibitors and DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, prevent the migration and invasion of KRAS-mutant cancer cells. Cytoskeleton. 2024. 81. online ahead of print
Ryuichi Masuzawa, Kazuya Takahashi, Kazunori Takano, Ichizo Nishino, Toshiyuki Sakai, Takeshi Endo. DA-Raf and the MEK inhibitor trametinib reverse skeletal myocyte differentiation inhibition or muscle atrophy caused by myostatin and GDF11 through the non-Smad Ras-ERK pathway. Journal of biochemistry. 2022. 171. 1. 109-122
Kazuya Takahashi, Eisuke Itakura, Kazunori Takano, Takeshi Endo. DA-Raf, a dominant-negative regulator of the Ras-ERK pathway, is essential for skeletal myocyte differentiation including myoblast fusion and apoptosis. Experimental cell research. 2019. 376. 2. 168-180
Emiri Kanno, Osamu Kawasaki, Kazuya Takahashi, Kazunori Takano, Takeshi Endo. DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor. Experimental cell research. 2018. 362. 1. 111-120
Ryo Maeda, Hiroyuki Tamashiro, Kazunori Takano, Hiro Takahashi, Hidefumi Suzuki, Shinta Saito, Waka Kojima, Noritaka Adachi, Kiyoe Ura, Takeshi Endo, et al. TBP-like Protein (TLP) Disrupts the p53-MDM2 Interaction and Induces Long-lasting p53 Activation. The Journal of biological chemistry. 2017. 292. 8. 3201-3212
